Urologix (ULGX) Stock Price, News & Analysis

Company Overview

Urologix (OTCMKTS:ULGX) is a medical device company specializing in the development and commercialization of minimally invasive therapies for urological conditions. The company’s core focus is on high-intensity focused ultrasound (HIFU) technology designed to treat benign prostatic hyperplasia (BPH) and localized prostate cancer. Urologix’s product portfolio delivers targeted tissue ablation while preserving surrounding structures, offering clinicians an alternative to more invasive surgical procedures.

The company’s flagship device, the Sonablate™ HIFU system, utilizes real-time imaging and precision-controlled ultrasound beams to non-invasively ablate prostate tissue. Urologix complements its hardware offerings with a comprehensive clinical support program, which includes physician training, procedure planning software, and ongoing technical service. By partnering with leading urology practices, hospitals and outpatient centers, the company helps integrate its technology into a range of patient care settings.

Founded in 1994 and headquartered in Minneapolis, Minnesota, Urologix has secured regulatory approvals in the United States, Europe and select Asia-Pacific markets. The company maintains an international distribution network and collaborates with regional distributors to expand access to its ultrasound-based therapies. Over the years, Urologix has invested in clinical trials and peer-reviewed studies aimed at validating safety, efficacy and long-term outcomes, underscoring its commitment to evidence-based treatment innovations.

Urologix is led by an executive team with extensive experience in medical device development, regulatory affairs and global commercialization. The management group, supported by a board of directors comprised of healthcare industry veterans, continues to advance the company’s R&D pipeline and strategic partnerships. With a focus on clinical excellence and patient-centric solutions, Urologix aims to broaden the adoption of HIFU technologies and enhance treatment options for men’s health worldwide.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ULGX Stock Analysis - Frequently Asked Questions

How do I buy shares of Urologix?

Shares of ULGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Urologix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Urologix investors own include Impel Pharmaceuticals (IMPL), Alarm.com (ALRM), Almonty Industries (ALMTF), Altice Europe (ALLVF), Alaska Air Group (ALK), Acadia Realty Trust (AKR) and Ark Mines (AHK).

Company Calendar

• Today: 7/18/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:ULGX
• CIK: 882873
• Web: www.urologix.com
• Phone: (763) 475-1400
• Fax: 763-404-8118
• Employees: 61
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -39.24